Olanzapine in the treatment of pervasive developmental disorders: A case series analysis

Journal of Psychiatry and Neuroscience

Volumn 29, Issue 1, 2004, Pages 57-60

  Stavrakaki, Chrissoula ^a,b   Antochi, Ruxandra ^b   Emery, Patricia C ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CLOBAZAM; CLONIDINE; DEXAMPHETAMINE; GABAPENTIN; HALOPERIDOL; METHYLPHENIDATE; OLANZAPINE; VALPROATE SEMISODIUM; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; DEVELOPMENTAL DISORDER; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FUNCTIONAL ASSESSMENT; HUMAN; MALE; NEPHROTOXICITY; PATIENT MONITORING; RATING SCALE; SEDATION; SIDE EFFECT; TREATMENT WITHDRAWAL; ADOLESCENT; AUTISM; CASE CONTROL STUDY; MIDDLE AGED; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CASE-CONTROL STUDIES; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 1642390112     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Cook EH. Autism: review of neurochemical investigation. Synapse 1990;6:292-308.
2. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment in children with autism and serious behavioral problems. N Engl J Med 2002;347:14-21.
3. Burns MJ. The pharmacology and toxicology of atypical antipsychotic agents. Clin Toxicol 2001;39(1):1-14.
4. Tran P, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-18.
5. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2000;57:841-9.
6. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001;158:131-4.
7. Keck PE Jr, Strakowski SM, McElroy SL. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psychiatry 2000;61(Suppl 3):4-9.
8. Rubin M. Use of atypical antipsychotics in children with mental retardation, autism, and other developmental disabilities. Psychiatr Ann 1997;27:219-21.
9. Horrigan JP, Barnhill LJ, Courvoisie HE. Olanzapine in PDD. J Am Acad Child Adolesc Psychiatry 1997;36:1166-7.
10. Potenza MN, Holes JP, Kanes SJ, McDougle CJ. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorder, an open-label pilot study. J Clin Psychopharmacol 1999;19:37-44.
11. Kemner C, Willemsen-Swinkels SH, de Jonge M, Tuynman-Qua H, van Engeland H. Open-label study of olanzapine in children with pervasive development disorder. J Clin Psychopharmacol 2002;22:455-60.
12. Malone RP, Cater J, Sheikh RM, Choudhury MS, Delaney MA. Olanzapine vs. haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 2001;40:887-94.
13. Demb HD, Roychoudhury K. Comments on "Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study." J Clin Psychopharmacol 2000;20:580-1.
14. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington: The Association; 1994.
15. Guy W. Clinical global impressions. In: EDCEU assessment manual for psychopharmacology. Rev. ed. US Department of Health, Education, and Welfare: Rockville (MD); 1976. p. 217-22.